Facebook
Twitter
Telegram
Report an ErrorSalarius Pharmaceuticals Balance Sheet 2011-2024 | SLRX
Annual Balance Sheet Salarius Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -11.1 M | -3.24 M | -9.83 M | -19.2 M | -22.4 M | -66.7 M | -33.9 M | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 39.2 K | 8.4 K | 30 K | 41.1 M | - | - | - |
Total Current Liabilities |
- | - | - | - | - | 1.11 M | 5.85 M | 3.89 M | 2.85 M | 1.07 M | - | - | - |
Total Liabilities |
1.3 M | 4.27 M | 2.11 M | 2.77 M | 3.31 M | 1.11 M | 5.89 M | 3.9 M | 2.88 M | 42.1 M | - | - | - |
Deferred Revenue |
- | - | - | - | 542 K | - | 72.2 K | 88.3 K | - | - | - | - | - |
Retained Earnings |
-76.3 M | -63.8 M | -32.2 M | - | -12.1 M | -133 M | -111 M | -76.6 M | -37.2 M | -8.01 M | - | - | - |
Total Assets |
6.59 M | 14.7 M | 40.8 M | 24.9 M | 13.9 M | 10.4 M | 35 M | 63.2 M | 95.1 M | 35.6 M | - | - | - |
Cash and Cash Equivalents |
5.9 M | 12.1 M | 29.2 M | 11.1 M | 3.74 M | 9.83 M | 19.2 M | 22.4 M | 66.7 M | 33.9 M | - | - | - |
Book Value |
5.29 M | 10.4 M | 38.7 M | 22.2 M | 10.6 M | 9.28 M | 29.1 M | 59.3 M | 92.2 M | -6.54 M | - | - | - |
Total Shareholders Equity |
5.29 M | 10.4 M | 38.7 M | 22.2 M | 10.6 M | -1.27 M | 29.1 M | 59.3 M | 92.2 M | -6.54 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Salarius Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.23 M | 1.3 M | 2.32 M | 3.64 M | 4.5 M | 4.27 M | 3.11 M | - | 2.09 M | 2.11 M | 1.61 M | 1.55 M | 1.99 M | 2.77 M | 2.77 M | 2.77 M | 2.77 M | 3.31 M | 3.31 M | 3.31 M | 3.31 M | 7.88 M | 7.88 M | 1.11 M | 1.11 M | 5.89 M | 5.89 M | 5.89 M | 5.89 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 2.88 M | 2.88 M | 2.88 M | 2.88 M | 1.12 M | 1.12 M | 1.12 M | 1.12 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 542 K | 542 K | 542 K | 542 K | - | 4.01 M | - | - | 72.2 K | 97.6 K | 96.7 K | 72.2 K | 88.3 K | 88.3 K | 88.3 K | 88.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-78.1 M | -76.3 M | -75.5 M | -73 M | -69.1 M | -63.8 M | -57.4 M | - | -38.3 M | -32.2 M | -28.1 M | -24.4 M | -21.3 M | -19.4 M | -19.4 M | -19.4 M | -19.4 M | -12.1 M | -12.1 M | -12.1 M | -12.1 M | -5.14 M | -5.14 M | -133 M | -133 M | -111 M | -111 M | -111 M | -111 M | -76.6 M | -76.6 M | -76.6 M | -76.6 M | -37.2 M | -37.2 M | -37.2 M | -37.2 M | -8.01 M | -8.01 M | -8.01 M | -8.01 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
4.88 M | 6.59 M | 8.4 M | 12.1 M | 10.1 M | 14.7 M | 19.7 M | - | 35.5 M | 40.8 M | 44.3 M | 47.4 M | 50.8 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 6.61 M | 6.61 M | 10.4 M | 10.4 M | 35 M | 35 M | 35 M | 35 M | 63.2 M | 63.2 M | 63.2 M | 63.2 M | 95.1 M | 95.1 M | 95.1 M | 95.1 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.37 M | 5.9 M | 7.58 M | 11.5 M | 9.27 M | 12.1 M | 16.8 M | 22.6 M | 24.2 M | 29.2 M | 31.9 M | 33.1 M | 36.6 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 3.74 M | 3.74 M | 3.74 M | 3.74 M | 3.23 M | 3.23 M | 9.83 M | 9.83 M | 19.2 M | 20.2 M | 19.2 M | 19.2 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 66.7 M | 66.7 M | 66.7 M | 66.7 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
3.65 M | 5.29 M | 6.08 M | 8.41 M | 5.56 M | 10.4 M | 16.6 M | - | 33.4 M | 38.7 M | 42.7 M | 45.9 M | 48.8 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | -1.27 M | -1.27 M | 9.28 M | 9.28 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 59.3 M | 59.3 M | 59.3 M | 59.3 M | 92.2 M | 92.2 M | 92.2 M | 92.2 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
3.65 M | 5.29 M | 6.08 M | 8.41 M | 5.56 M | 10.4 M | 16.6 M | 30.9 M | 33.4 M | 38.7 M | 42.7 M | 45.9 M | 48.8 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | -1.27 M | -1.27 M | 9.28 M | 9.28 M | -2.9 M | 29.1 M | 29.1 M | 29.1 M | 59.3 M | 59.3 M | 59.3 M | 59.3 M | 92.2 M | 92.2 M | 92.2 M | 92.2 M | -6.54 M | -6.54 M | -6.54 M | -6.54 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency